2024 Global Hepatitis A, B, C, D, E Diagnostics Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and NAT Tests, Technology and Instrumentation Review, Opportunities for Suppliers
The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan.The report is available by section, and can be customized to specific information needs and budget.Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets:%li%Hospitals%li%Commercial/Private Labs%li%Blood Banks%li%Physician Offices%li%Public Health LabsFor each country, in addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests.Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.Contains 320 pages and 93 tables
I. Introduction
II. Worldwide Market and Technology Overview
A. Background
B. Hepatitis A
C. Hepatitis B
D. Hepatitis C
0 CLASSIFICATION
0 TRANSMISSION OF INFECTION
0 OCCUPATIONAL HAZARDS
0 ACUTE HEPATITIS
0 DIAGNOSIS OF ACUTE INFECTION
0 CHRONIC HEPATITIS
0 HCV AND OTHER CHRONIC LIVER DISEASES
0 ALCOHOLIC LIVER DISEASE
0 HEPATITIS B COINFECTION
0 CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
0 DIAGNOSTIC TESTS
0 POSSIBLE INDICATIONS FOR HCV RNA TESTING
0 CONCLUSIONS AND FUTURE DIRECTION
E. Hepatitis D
0 HISTORICAL PERSPECTIVE
0 EPIDEMIOLOGY
0 HBV-HDV 'COINFECTION' VS. 'SUPERINFECTION'
0 METHODS OF DETECTING HDV
0 PREVENTION
F. Hepatitis E
0 BACKGROUND
0 PREVALENCE OF THE DISEASE
0 DIAGNOSTIC TESTS
0 EPIDEMIOLOGIC SEROSURVEYS
0 SEROLOGIC CROSS-REACTIVITY
G. Hepatitis G
0 VACCINES AND DRUGS
H. Instrumentation Review and Market Needs
0 ABBOTT AXSYM
Table of Contents (continued)
0 ABBOTT IMX/IMX SELECT
0 ANAGEN AN2000/AURAFLEX
0 BECKMAN COULTER ACCESS
0 BIOCHEM PHARMA/SR1
0 BIOMERIEUX/VITEK VIDAS
0 BIOTROL SYSTEM 7000
0 CHIRON ACS: CENTAUR
0 CHIRON ACS:
0 J&J DIAGNOSTICS/AMERSHAM AMERLITE
0 J&J DIAGNOSTICS VITROS ECI
0 OLYMPUS PK310
0 ROCHE COBAS CORE
0 ROCHE ELECSYS 1010/2010
0 ROCHE ES
0 ROCHE ES
0 ROCHE ES 300/300AL
0 SIEMENS ELISA PROCESSOR II/III
0 SIEMENS IMMUNO
0 SIEMENS/OPUS/PLUS/MAGNUM
0 SIEMENS STRATUS
0 TOSOH AIA-1200/1200DX/NEXIA/600
0 WALLAC/PHARMACIA DELFIA
I. Emerging Diagnostic Technologies
1. DNA PROBES
a. Technology Overview
b. Amplification Methods
0 POLYMERASE CHAIN REACTION
- Robotics
- Temperature Cyclers
- PCR Variations
0 IMMUNO-PCR
0 QC-PCR
0 DAP-PCR
0 LIGASE CHAIN REACTION
0 BRANCHED DNA
0 Q-BETA REPLICASE
0 NUCLEIC-ACID SEQUENCE-BASED
0 STRAND DISPLACEMENT ACTIVATION
0 SELF-SUSTAINED SEQUENCE REPLICASE
2. MONOCLONAL ANTIBODIES
3. IMMUNOASSAYS
II. Worldwide Market and Technology Overview
A. Background
B. Hepatitis A
C. Hepatitis B
D. Hepatitis C
0 CLASSIFICATION
0 TRANSMISSION OF INFECTION
0 OCCUPATIONAL HAZARDS
0 ACUTE HEPATITIS
0 DIAGNOSIS OF ACUTE INFECTION
0 CHRONIC HEPATITIS
0 HCV AND OTHER CHRONIC LIVER DISEASES
0 ALCOHOLIC LIVER DISEASE
0 HEPATITIS B COINFECTION
0 CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
0 DIAGNOSTIC TESTS
0 POSSIBLE INDICATIONS FOR HCV RNA TESTING
0 CONCLUSIONS AND FUTURE DIRECTION
E. Hepatitis D
0 HISTORICAL PERSPECTIVE
0 EPIDEMIOLOGY
0 HBV-HDV 'COINFECTION' VS. 'SUPERINFECTION'
0 METHODS OF DETECTING HDV
0 PREVENTION
F. Hepatitis E
0 BACKGROUND
0 PREVALENCE OF THE DISEASE
0 DIAGNOSTIC TESTS
0 EPIDEMIOLOGIC SEROSURVEYS
0 SEROLOGIC CROSS-REACTIVITY
G. Hepatitis G
0 VACCINES AND DRUGS
H. Instrumentation Review and Market Needs
0 ABBOTT AXSYM
Table of Contents (continued)
0 ABBOTT IMX/IMX SELECT
0 ANAGEN AN2000/AURAFLEX
0 BECKMAN COULTER ACCESS
0 BIOCHEM PHARMA/SR1
0 BIOMERIEUX/VITEK VIDAS
0 BIOTROL SYSTEM 7000
0 CHIRON ACS: CENTAUR
0 CHIRON ACS:
0 J&J DIAGNOSTICS/AMERSHAM AMERLITE
0 J&J DIAGNOSTICS VITROS ECI
0 OLYMPUS PK310
0 ROCHE COBAS CORE
0 ROCHE ELECSYS 1010/2010
0 ROCHE ES
0 ROCHE ES
0 ROCHE ES 300/300AL
0 SIEMENS ELISA PROCESSOR II/III
0 SIEMENS IMMUNO
0 SIEMENS/OPUS/PLUS/MAGNUM
0 SIEMENS STRATUS
0 TOSOH AIA-1200/1200DX/NEXIA/600
0 WALLAC/PHARMACIA DELFIA
I. Emerging Diagnostic Technologies
1. DNA PROBES
a. Technology Overview
b. Amplification Methods
0 POLYMERASE CHAIN REACTION
- Robotics
- Temperature Cyclers
- PCR Variations
0 IMMUNO-PCR
0 QC-PCR
0 DAP-PCR
0 LIGASE CHAIN REACTION
0 BRANCHED DNA
0 Q-BETA REPLICASE
0 NUCLEIC-ACID SEQUENCE-BASED
0 STRAND DISPLACEMENT ACTIVATION
0 SELF-SUSTAINED SEQUENCE REPLICASE
2. MONOCLONAL ANTIBODIES
3. IMMUNOASSAYS
